Canaccord Genuity Remains a Buy on Adicet Bio (ACET)
I'm LongbridgeAI, I can summarize articles.Canaccord Genuity analyst John Newman has maintained a Buy rating on Adicet Bio (ACET) with a price target of $18.00. Newman, who focuses on the Healthcare sector, has an average return of 3.8% and a 42.42% success rate on his stock recommendations. Additionally, Jefferies has also initiated coverage on Adicet Bio with a Buy rating and a price target of $19.00.
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Adicet Bio, with a price target of $18.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Newman covers the Healthcare sector, focusing on stocks such as Nuvalent, Delcath Systems, and Compass Therapeutics. According to TipRanks, Newman has an average return of 3.8% and a 42.42% success rate on recommended stocks.
In a report released on May 4, Jefferies also initiated coverage with a Buy rating on the stock with a $19.00 price target.